ScholarLens Back to search
2010•Pharmacology & TherapeuticsRequires access

Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers

Erik De Clercq

Open publisher page 122 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 122 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Plerixafor, CXCR4 antagonist, CXCR4, Stem cell, Progenitor cell, Cancer research, Pharmacology, Haematopoiesis

Related papers

Related paper 1Related paper 2
Back to paper searchBrowse research topicsOriginal source
Recent advances on the use of the CXCR4 antagonist plerixafor (AMD3100, Mozobil™) and potential of other CXCR4 antagonists as stem cell mobilizers — Research Paper | ScholarLens